Cargando…
Predicting amyloid PET positivity using plasma p‐tau181 and other blood‐based biomarkers
INTRODUCTION: This study aimed to determine the efficacy of combining plasma phosphorylated tau (p‐tau)181, amyloid beta (Aβ)42/Aβ40, neurofilament light (NfL), and apolipoprotein E (APOE) genotypes for detecting positive amyloid positron emission tomography (PET), which is little known in the Asian...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654468/ https://www.ncbi.nlm.nih.gov/pubmed/38026758 http://dx.doi.org/10.1002/dad2.12502 |
_version_ | 1785147847161675776 |
---|---|
author | Kwon, Hyuk Sung Lee, Eun‐Hye Kim, Hyung‐Ji Park, So‐Hee Park, Hyun‐Hee Jeong, Jee Hyang Koh, Seong‐Ho Choi, Seong Hye Lee, Jae‐Hong |
author_facet | Kwon, Hyuk Sung Lee, Eun‐Hye Kim, Hyung‐Ji Park, So‐Hee Park, Hyun‐Hee Jeong, Jee Hyang Koh, Seong‐Ho Choi, Seong Hye Lee, Jae‐Hong |
author_sort | Kwon, Hyuk Sung |
collection | PubMed |
description | INTRODUCTION: This study aimed to determine the efficacy of combining plasma phosphorylated tau (p‐tau)181, amyloid beta (Aβ)42/Aβ40, neurofilament light (NfL), and apolipoprotein E (APOE) genotypes for detecting positive amyloid positron emission tomography (PET), which is little known in the Asian population, in two independent cohorts. METHODS: Biomarkers were measured using a single‐molecule array (Simoa) in a cohort study (Asan). All participants underwent amyloid PET. Significant changes in the area under the curve (AUC) and Akaike Information Criterion values were considered to determine the best model. The generalizability of this model was tested using another cohort (KBASE‐V). RESULTS: In the Asan cohort, after adjusting for age and sex, p‐tau181 (AUC = 0.854) or APOE ε4 status (AUC = 0.769) distinguished Aβ status with high accuracy. Combining them or adding NfL and Aβ42/40 improved model fitness. The best‐fit model included the plasma p‐tau181, APOE ε4, NfL and Aβ42/40. The models established from the Asan cohort were tested in the KBASE‐V cohort. Additionally, in the KBASE‐V cohort, these three biomarker models had similar AUC in cognitively unimpaired (AUC = 0.768) and mild cognitive impairment (MCI) (AUC = 0.997) participants. CONCLUSIONS: Plasma p‐tau181 showed a high performance in determining Aβ‐PET positivity. Adding plasma NfL and APOE ε4 status improved the model fit without significant improvement in AUC. |
format | Online Article Text |
id | pubmed-10654468 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106544682023-11-16 Predicting amyloid PET positivity using plasma p‐tau181 and other blood‐based biomarkers Kwon, Hyuk Sung Lee, Eun‐Hye Kim, Hyung‐Ji Park, So‐Hee Park, Hyun‐Hee Jeong, Jee Hyang Koh, Seong‐Ho Choi, Seong Hye Lee, Jae‐Hong Alzheimers Dement (Amst) Research Articles INTRODUCTION: This study aimed to determine the efficacy of combining plasma phosphorylated tau (p‐tau)181, amyloid beta (Aβ)42/Aβ40, neurofilament light (NfL), and apolipoprotein E (APOE) genotypes for detecting positive amyloid positron emission tomography (PET), which is little known in the Asian population, in two independent cohorts. METHODS: Biomarkers were measured using a single‐molecule array (Simoa) in a cohort study (Asan). All participants underwent amyloid PET. Significant changes in the area under the curve (AUC) and Akaike Information Criterion values were considered to determine the best model. The generalizability of this model was tested using another cohort (KBASE‐V). RESULTS: In the Asan cohort, after adjusting for age and sex, p‐tau181 (AUC = 0.854) or APOE ε4 status (AUC = 0.769) distinguished Aβ status with high accuracy. Combining them or adding NfL and Aβ42/40 improved model fitness. The best‐fit model included the plasma p‐tau181, APOE ε4, NfL and Aβ42/40. The models established from the Asan cohort were tested in the KBASE‐V cohort. Additionally, in the KBASE‐V cohort, these three biomarker models had similar AUC in cognitively unimpaired (AUC = 0.768) and mild cognitive impairment (MCI) (AUC = 0.997) participants. CONCLUSIONS: Plasma p‐tau181 showed a high performance in determining Aβ‐PET positivity. Adding plasma NfL and APOE ε4 status improved the model fit without significant improvement in AUC. John Wiley and Sons Inc. 2023-11-16 /pmc/articles/PMC10654468/ /pubmed/38026758 http://dx.doi.org/10.1002/dad2.12502 Text en © 2023 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Kwon, Hyuk Sung Lee, Eun‐Hye Kim, Hyung‐Ji Park, So‐Hee Park, Hyun‐Hee Jeong, Jee Hyang Koh, Seong‐Ho Choi, Seong Hye Lee, Jae‐Hong Predicting amyloid PET positivity using plasma p‐tau181 and other blood‐based biomarkers |
title | Predicting amyloid PET positivity using plasma p‐tau181 and other blood‐based biomarkers |
title_full | Predicting amyloid PET positivity using plasma p‐tau181 and other blood‐based biomarkers |
title_fullStr | Predicting amyloid PET positivity using plasma p‐tau181 and other blood‐based biomarkers |
title_full_unstemmed | Predicting amyloid PET positivity using plasma p‐tau181 and other blood‐based biomarkers |
title_short | Predicting amyloid PET positivity using plasma p‐tau181 and other blood‐based biomarkers |
title_sort | predicting amyloid pet positivity using plasma p‐tau181 and other blood‐based biomarkers |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654468/ https://www.ncbi.nlm.nih.gov/pubmed/38026758 http://dx.doi.org/10.1002/dad2.12502 |
work_keys_str_mv | AT kwonhyuksung predictingamyloidpetpositivityusingplasmaptau181andotherbloodbasedbiomarkers AT leeeunhye predictingamyloidpetpositivityusingplasmaptau181andotherbloodbasedbiomarkers AT kimhyungji predictingamyloidpetpositivityusingplasmaptau181andotherbloodbasedbiomarkers AT parksohee predictingamyloidpetpositivityusingplasmaptau181andotherbloodbasedbiomarkers AT parkhyunhee predictingamyloidpetpositivityusingplasmaptau181andotherbloodbasedbiomarkers AT jeongjeehyang predictingamyloidpetpositivityusingplasmaptau181andotherbloodbasedbiomarkers AT kohseongho predictingamyloidpetpositivityusingplasmaptau181andotherbloodbasedbiomarkers AT choiseonghye predictingamyloidpetpositivityusingplasmaptau181andotherbloodbasedbiomarkers AT leejaehong predictingamyloidpetpositivityusingplasmaptau181andotherbloodbasedbiomarkers |